Actionable news
0
All posts from Actionable news
Actionable news in REGN: Regeneron Pharmaceuticals, Inc.,

Novartis eye drug works at less frequent dosing than rival's

ZURICH, June 20 (Reuters) - Novartis eye drug RTH258 works as well as a rival product from Regeneron and at less frequent dosing in clinical trials, the Swiss drugmaker said on Tuesday, boosting its shares.

The drug, whose generic name is brolucizumab, aims to treat neovascular age-related macular degeneration (nAMD), the leading cause of severe vision loss and blindness in people over the age of 65 in North America, Europe, Australia and Asia.

Head-to-head late-stage trials showed RTH258 worked as...


More